Duration of viral infectiousness and correlation with symptoms and diagnostic testing in non-hospitalized adults during acute SARS-CoV-2 infection: A longitudinal cohort study

Submitted by galeadmin on Mon, 04/03/2023 - 10:07

In a collaborative study we evaluated viral shedding, and we isolated and sequenced virus across time, comparing outcomes with current diagnostic testing and clinical features of infection and recovery.  Remarkably, some people are viral RNA+ for up to 30 days following COVID symptom onset.

Read the study: https://pubmed.ncbi.nlm.nih.gov/36913789/

A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity

Submitted by galeadmin on Mon, 04/03/2023 - 10:05

Targeting RIG-I with small molecules for induction of innate immunity enhances influenza A virus vaccine immunity including heterologous immunity against multiple viral HA types. This study reveals RIG-I as a valid drug target for strategies to effectively enhance broad spectrum antiviral immunity against virus infection. 

Innate immune regulation in HIV latency models

Submitted by galeadmin on Tue, 01/24/2023 - 14:02

A study led by Dr. Rebecca Olson, the Gale lab shows that HIV latency and viral suppression each link with cell-intrinsic defects in specific innate immune gene expression. We identify a set of innate immune effector genes as candidate viral latency restriction factors whose expression and function could possibly mitigate establishing latent HIV infection.

The Gale lab has been named on the annual Highly Cited Researchers 2022 list from Clarivate.

Submitted by galeadmin on Tue, 11/15/2022 - 09:40

The Gale lab has been named on the annual Highly Cited Researchers each year since 2014, and has made this list again for 2022 from Clarivate. This ranking places our group among the top 1% of all cited research teams in the World across the fields of innate immunity, microbiology, and infectious disease. The Gale lab is joined by additional research groups around the world as leaders in their respective fields.


Our response to COVID-19 and the SARS-CoV-2 pandemic

Submitted by galeadmin on Tue, 01/12/2021 - 17:18

We are collaborating with local and international colleagues in the response to the SARS-CoV-2 pandemic. These activities include directing the laboratory analysis to assess the efficacy of the Moderna vaccine across clinical trials in efforts that have now facilitated the US FDA and CDC approval of this vaccine for emergency use to vaccinate the American population and international populations.  

We have also: